18 results about "Urinary system" patented technology

The present invention provides constructs including a tubular biodegradable polyglycolic acid scaffold, wherein the scaffold may be coated with extracellular matrix proteins and substantially acellular. The constructs can be utilized as an arteriovenous graft, a coronary graft, a peripheral artery bypass conduit, or a urinary conduit. The present invention also provides methods of producing such constructs.

The invention is suitable for the technical field of medical image processing and artificial intelligence, and provides a urinary system tumor bone metastasis diagnosis method based on deep learning and bone positioning, and the method comprises the steps: collecting and preprocessing multi-modal medical data containing PET / CT images; segmenting a skeleton region by adopting a deep learning model, and realizing focus segmentation in the skeleton region; a lightweight skeleton segmentation network is constructed, and efficient and fine skeleton segmentation is realized through an encoder-decoder structure; pET metabolic features, CT morphological features and texture features are extracted and fused, and a radiomics feature matrix is constructed; carrying out cancer species specificity analysis based on the radiomics characteristic matrix, and constructing an intelligent diagnosis model by utilizing a machine learning algorithm; and finally, outputting a structured report containing the focus position, the type, the cancer classification and the diagnosis confidence. According to the invention, through lightweight network design and multi-modal feature fusion, the efficiency and accuracy of skeleton segmentation and focus diagnosis are significantly improved, and the method is suitable for clinical real-time auxiliary diagnosis.

The three-channel cystoscope catheter comprises a cystoscope bridge, an instrument body, a valve body, a catheter body and a catheter head, the catheter head is arranged on the front end portion where the catheter body is located, the valve body is arranged on the rear end portion where the catheter body is located, and the catheter body is of a tubular structure penetrating front and back; an instrument cavity and a cystoscope cavity which are mutually independent are formed in the catheter body in the tubular axis direction, and a water outlet cavity is formed in a gap between the outer walls of the instrument cavity and the cystoscope cavity and the inner wall of the cavity of the catheter body; a water outlet hole communicated with the water outlet cavity channel is formed in the outer wall of the rear end part where the catheter body is located; the instrument body is arranged at the rear end of the valve body and communicated with the end of the instrument cavity and the end of the cystoscope cavity. The whole device adopts the independent instrument cavity and the water outlet cavity, continuous convection is formed when water is injected, the visual field of the cystoscope in a human body is kept clear, the cystoscope is safe, and urinary system examination, sampling, minimally invasive surgery and the like are completed effectively and accurately.

The present disclosure relates to the detection of one or more types of urological cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urological cancer (e.g., urothelial carcinoma and / or renal cell carcinoma) in a biological sample from a subject having or suspected of having urological cancer.

Provided is a method for preventing or treating urological chronic pelvic pain syndrome (UCPPS) in a subject that includes administering an effective amount of cerium oxide nanoparticles (CeNPs) to the subject. Also provided is a method for preventing or treating an UCPPS in a subject that includes administering to the subject a pharmaceutical composition comprising an effective amount of the CeNPs and a pharmaceutically acceptable carrier thereof.

This invention relates to compositions and methods relating to a combination of naturally-occurring active ingredients useful for the regulation of kidney and excretory system function. The combination of active ingredients, comprising vitamin B6, vitamin E, iron, roundhead lespedeza, birch leaf, and red bilberry, improves the function of kidney structures. The present invention may be used to achieve lower blood nitrogen content, including help to eliminate creatinine, urea, uric acid, by improving glomerular filtration and thus delaying hemodialysis. The present invention may be used to achieve a pronounced anti-inflammatory effect on the kidneys and the urinary tract. The present invention may also be used on its own or as a part of conventional treatment for a long time or indefinitely.

This invention provides a novel medical device for performing precise urological procedures, specifically focusing on urological stone removal. The illustrative Stone Removal Robot leverages multiple subsystems to autonomously remove stones while using real-time image guidance for precise targeting and minimal collateral damage. This system is particularly suited for use in urology, though its applications can extend to other surgical fields. The key benefit of this invention lies in its ability to provide enhanced accuracy, reducing the potential for human error, while integrating multiple lithotripsy methods termed herein, Method1, Method2, Method3, which may incorporate cooling to protect surrounding tissues. The system can be adapted for autonomous operation.

The present disclosure provides compositions and methods for the treatment of inflammation in urological pathologies.

The present application relates to methods of treating urologic chronic pelvic pain syndrome (UCPPS) or pain associated with UCPPS using a compound of Formula I, or a pharmaceutically acceptable salt, prodrug and / or solvate thereof. UCPPS encompasses interstitial cystitis / bladder pain syndrome (IC / BPS) and chronic prostatitis / chronic pelvic pain syndrome (CP / CPPS). (I)

It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and / or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and / or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and / or other agents.

Therapeutic agents and treatment methods for urologic cancers, particularly urologic cancers with reduced lysine (K)-specific demethylase 6A (KDM6A) function, the agents and methods being characterized by suppressing both IL-6 activity and CCR2 / CCL2 activity, are provided.

Hydrolyzed collagen compositions are described that are used for treatment of impaired tissue including mucosal tissue or to prevent damage to healthy tissue. These compositions function to treat mucosal tissues found in the digestive, urinary, respiratory and reproductive systems. Oral or topical, site-specific delivery of the compositions may be via liquid, spray, gel, powder, tablet, capsule, or sheet form.

A method of treating human or animal tissue, the method comprising the step of: i. directing a stream of an aqueous liquid comprising gas bubbles excited by acoustic energy towards a wound or anatomical pocket in human or animal tissue, or towards an anatomical space or potential space in human or animal tissue, or towards soft or hard tissue in an oral cavity or elsewhere in the human or animal body, or towards tissue in a nasal cavity, or towards tissue associated with sinuses, eye, ear, digestive and genito-urinary systems, thereby to treat the human or animal tissue with the stream. The output stream can clean a wound in human or animal tissue, and can treat the wound by healing the wound, for example by stimulating fibroblasts in the wound tissue and causing, promoting or enhancing re-epithelialisation of epidermal tissue in the wound.

The present invention relates to the compound 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological conditions including grade IV glioblastoma, grade 3 glioma, embryonal tumor, pituitary tumor, meningioma, hemangiopericytoma, hemangioblastoma, mesothelioma, cholangiocarcinoma, exocrine pancreatic cancer, neuroendocrine pancreatic cancer, rectal cancer, urinary tract cancer, bladder adenocarcinoma, and esophageal cancer, as well as for use in the treatment of peripheral diabetic neuropathy, spinal cord injury, postherpetic neuralgia, chemotherapeutic agents, antitumor agents, cancer, fibromyalgia, or neuropathic pain caused by hepatitis. The present invention also relates to pharmaceutical compositions comprising 2-hydroxy-octadecene-9-cis-oate.

Providing a controlled-release formulation containing dorotaberine or its salts, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. [Solution] The present invention provides a controlled-release formulation containing dorotaberine or a salt thereof, or an active substance with a similar tendency to degrade through oxidation / hydrolysis. The present invention provides a once- or twice-daily controlled-release formulation of dorotaberine or a salt thereof that avoids fluctuations in plasma levels, reduces pill burden and side effects through a simplified dosing schedule, and consequently improves patient compliance. The present invention also provides a method for preparing a controlled-release formulation of dorotaberine or a salt thereof. The present invention further provides a controlled-release formulation of dorotaberine or a salt thereof for the treatment of at least one symptom of gastrointestinal, biliary, urinary, and gynecological disorders characterized by a spastic state of smooth muscle in a subject.

A non-invasive technique for enhancing the delivery of botulinum toxins through the skin, utilizing low-frequency ultrasound as a pretreatment, is provided. The ultrasound- facilitated transdermal delivery approach provides an efficient, comfortable and needle-free alternative to conventional injection-based administration of botulinum toxins, and is applicable to a wide range of therapeutic and cosmetic uses, including, reducing or modulating sweat gland activity, relaxing or inhibiting muscle activity, alleviating pain, minimizing wrinkles or fine lines, and treating or preventing pathologies such as neuromuscular and neurological disorders, glandular dysfunction, urological conditions, ophthalmological disorders, gastrointestinal conditions and / or respiratory disorders

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The present disclosure relates to a closed-loop neuromodulation system based on sacral nerve electrophysiological activity monitoring. The closed-loop neuromodulation system includes an implantable neuromodulation module, a programming module, and a server module. The implantable neuromodulation module obtains monitoring data based on an implantable electrode and synchronously obtains a local field potential variation signal generated in a patient with urinary tract dysfunction during the sacral nerve conduction, and applies an electrical stimulation pulse to the sacral nerve of the patient when an abnormal monitoring result of nerve afferent impulses associated with urinary urgency symptom of the patient is obtained based on the local field potential variation signal. The server module stores the monitoring data and sends an intelligent recognition model that is pre-trained to the implantable neuromodulation module and the programming module, respectively.